|
|
||||||||
1 St. Vincent's Institute of Medical Research and 2 Department of Intensive Care, St. Vincent's Hospital, Fitzroy, Victoria 3065, Australia; and 3 Institut für Biochemie, Technische Universität Darmstadt, 64287 Darmstadt, Germany
We used cardiopulmonary bypass (CPB) as a model of activation of the contact system and investigated the involvement of the plasma and tissue kallikrein-kinin systems (KKS) in this process. Circulating levels of bradykinin and kallidin and their metabolites, plasma and tissue kallikrein, low and high molecular weight kininogen, and kallistatin were measured before, during, and 1, 4, and 10 h after CPB in subjects undergoing cardiac surgery. Bradykinin peptide levels increased 10- to 20-fold during the first 10 min, returned toward basal levels by 70 min of CPB, and remained 1.2- to 2.5-fold elevated after CPB. Kallidin peptide levels showed little change during CPB, but they were elevated 1.7- to 5.2-fold after CPB. There were reductions of 80 and 60% in plasma and tissue kallikrein levels, respectively, during the first minute of CPB. Kininogen and kallistatin levels were unchanged. Angiotensin-converting enzyme inhibition did not amplify the increase in bradykinin levels during CPB. Aprotinin administration prevented activation of the KKS. The changes in circulating kinin and kallikrein levels indicate activation of both the plasma and tissue KKS during activation of the contact system by CPB.
contact system; bradykinin; kallidin; angiotensin-converting enzyme inhibition; kininogen; kallistatin; aprotinin
This article has been cited by other articles:
![]() |
H. Yoon, S. I. Blaber, D. M. Evans, J. Trim, M. A. Juliano, I. A. Scarisbrick, and M. Blaber Activation profiles of human kallikrein-related peptidases by proteases of the thrombostasis axis Protein Sci., November 1, 2008; 17(11): 1998 - 2007. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. H. Rosner, D. Portilla, and M. D. Okusa Analytic Reviews: Cardiac Surgery as a Cause of Acute Kidney Injury: Pathogenesis and Potential Therapies J Intensive Care Med, January 1, 2008; 23(1): 3 - 18. [Abstract] [PDF] |
||||
![]() |
S. Allen, W. T McBride, I. S Young, S. W MacGowan, T. J McMurray, S. Prabhu, S P. Penugonda, and M. A Armstrong A clinical, renal and immunological assessment of Surface Modifying Additive Treated (SMARTTM) cardiopulmonary bypass circuits Perfusion, September 1, 2005; 20(5): 255 - 262. [Abstract] [PDF] |
||||
![]() |
J. M. Costello, C. L. Backer, A. de Hoyos, H. J. Binns, and C. Mavroudis Aprotinin reduces operative closure time and blood product use after pediatric bypass Ann. Thorac. Surg., April 1, 2003; 75(4): 1261 - 1266. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |